Your browser doesn't support javascript.
loading
[Design and immunogenicity evaluation for the bacteria-like particle vaccine against swine type O foot-and-mouth disease virus].
Hou, Liting; Chen, Jin; Qiao, Xuwen; Yu, Xiaoming; Hou, Jibo; Zheng, Qisheng; Li, Jinnian.
Affiliation
  • Hou L; College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, Anhui, China.
  • Chen J; National Research Center of Veterinary Biological Engineering and Technology, Nanjing 210014, Jiangsu, China.
  • Qiao X; National Research Center of Veterinary Biological Engineering and Technology, Nanjing 210014, Jiangsu, China.
  • Yu X; National Research Center of Veterinary Biological Engineering and Technology, Nanjing 210014, Jiangsu, China.
  • Hou J; National Research Center of Veterinary Biological Engineering and Technology, Nanjing 210014, Jiangsu, China.
  • Zheng Q; National Research Center of Veterinary Biological Engineering and Technology, Nanjing 210014, Jiangsu, China.
  • Li J; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, Jiangsu, China.
Sheng Wu Gong Cheng Xue Bao ; 33(2): 217-227, 2017 Feb 25.
Article in Zh | MEDLINE | ID: mdl-28956378
ABSTRACT
Based on gram positive enhancer matrix displaying technology, we designed and evaluated a bacteria-like particle vaccine against swine type O Foot-and-mouth disease virus. Three optimized genes of type O Foot-and-mouth disease virus strain Mya98 were cloned into recombinant prokaryotic expression vector pQZ-PA and renamed as pQZ-BT1B-PA, pQZ-BT2B-PA and pQZ-B (T1BT2) 4B-PA, fused with an anchor protein (PA) binding to Gram-positive enhancer matrix (GEM) particles specifically. The protein expression was identified with SDS-PAGE and Western blotting, and then purified with GEM particles. Five-week old female mice were randomly divided into six groups and all the immunization was developed according to subcutaneous injection. Mice in the first three groups were injected with 50 µg/dose GEM-BT1B, GEM-BT2B and GEM-B (T1BT2) 4B, respectively. Mice in the fourth group were immunized with commercial peptide vaccine as positive control. The fifth group vaccinated with host E. coli transformed with pQZ-PA fulfilled as negative control. Mice in the last group injected with sterile PBS served as blank control. The humoral immunity of recombinant protein vaccine was evaluated with peptide-specific antibody and LPB antibody. The cellular immunity was evaluated with lymphocyte proliferation test and cytokine expression detection. SDS-PAGE and Western blotting showed that the most part of soluble target fusion protein have been purified and displayed on GEM particles. Vaccine GEM-B (T1BT2) 4B stimulated mice produce not only higher level of specific antibody against peptide and Foot-and-mouth disease virus specific liquid phase blocking antibody, but also more vigorous spleen lymph proliferation and higher levels of Th1 type cytokines. To summarize, vaccine of GEM-B (T1BT2) 4B possessed good immunogenicity and opened a new way for further Foot-and-mouth disease virus subunit vaccine design.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Foot-and-Mouth Disease Virus / Foot-and-Mouth Disease / Immunogenicity, Vaccine Limits: Animals Language: Zh Journal: Sheng Wu Gong Cheng Xue Bao Journal subject: BIOTECNOLOGIA Year: 2017 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Foot-and-Mouth Disease Virus / Foot-and-Mouth Disease / Immunogenicity, Vaccine Limits: Animals Language: Zh Journal: Sheng Wu Gong Cheng Xue Bao Journal subject: BIOTECNOLOGIA Year: 2017 Document type: Article Affiliation country: China